uniQure (NASDAQ:QURE) Upgraded by Mizuho to “Outperform” Rating

Mizuho upgraded shares of uniQure (NASDAQ:QURE) from a neutral rating to an outperform rating in a research note published on Wednesday, Marketbeat.com reports. They currently have $35.00 price objective on the biotechnology company’s stock, up from their prior price objective of $12.00.

A number of other research analysts have also weighed in on the company. Wolfe Research started coverage on uniQure in a report on Monday, February 23rd. They set a “peer perform” rating for the company. Cantor Fitzgerald reissued a “neutral” rating and issued a $9.00 price target (down from $55.00) on shares of uniQure in a report on Monday, March 2nd. The Goldman Sachs Group cut their price objective on shares of uniQure from $37.00 to $9.00 and set a “neutral” rating for the company in a research report on Tuesday, March 3rd. Royal Bank Of Canada raised shares of uniQure from a “sector perform” rating to an “outperform” rating and upped their target price for the stock from $11.00 to $35.00 in a report on Monday. Finally, Leerink Partners reiterated an “outperform” rating and issued a $35.00 target price on shares of uniQure in a research note on Monday, March 2nd. Ten research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, uniQure presently has a consensus rating of “Moderate Buy” and an average target price of $43.25.

uniQure Trading Down 3.8%

NASDAQ:QURE opened at $17.56 on Wednesday. uniQure has a 1 year low of $7.76 and a 1 year high of $71.50. The stock’s fifty day moving average price is $21.67 and its two-hundred day moving average price is $29.58. The company has a debt-to-equity ratio of 0.25, a current ratio of 10.43 and a quick ratio of 10.43. The company has a market cap of $1.10 billion, a P/E ratio of -5.09 and a beta of 0.73.

uniQure (NASDAQ:QURE) last announced its quarterly earnings results on Monday, March 2nd. The biotechnology company reported ($0.56) earnings per share for the quarter, beating the consensus estimate of ($0.93) by $0.37. uniQure had a negative return on equity of 174.03% and a negative net margin of 1,236.00%.The company had revenue of $5.57 million during the quarter, compared to analysts’ expectations of $4.84 million. As a group, analysts expect that uniQure will post -3.75 EPS for the current year.

Insider Activity

In related news, Director Robert Gut sold 25,613 shares of the firm’s stock in a transaction that occurred on Monday, January 12th. The shares were sold at an average price of $24.62, for a total value of $630,592.06. Following the sale, the director directly owned 32,342 shares of the company’s stock, valued at $796,260.04. This trade represents a 44.19% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Jack Kaye sold 6,390 shares of uniQure stock in a transaction that occurred on Friday, January 9th. The shares were sold at an average price of $27.28, for a total transaction of $174,319.20. Following the sale, the director owned 20,439 shares of the company’s stock, valued at approximately $557,575.92. The trade was a 23.82% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 81,399 shares of company stock worth $1,527,645. Company insiders own 4.79% of the company’s stock.

Institutional Trading of uniQure

Institutional investors and hedge funds have recently made changes to their positions in the stock. Flax Pond Capital LLC bought a new stake in shares of uniQure during the 4th quarter worth $3,506,000. Seven Fleet Capital Management LP bought a new position in uniQure in the fourth quarter valued at $209,000. Virtus Investment Advisers LLC increased its stake in uniQure by 91.6% in the fourth quarter. Virtus Investment Advisers LLC now owns 13,636 shares of the biotechnology company’s stock valued at $326,000 after acquiring an additional 6,520 shares during the last quarter. SummitTX Capital L.P. raised its position in uniQure by 386.3% during the fourth quarter. SummitTX Capital L.P. now owns 27,708 shares of the biotechnology company’s stock valued at $663,000 after purchasing an additional 22,010 shares in the last quarter. Finally, Suvretta Capital Management LLC purchased a new stake in uniQure during the fourth quarter valued at about $29,116,000. Hedge funds and other institutional investors own 78.83% of the company’s stock.

Key uniQure News

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: Several analyst upgrades and bullish reports have pushed optimism around the company’s pipeline — Mizuho upgraded QURE to “outperform” with a $35 target (up from $12), and other firms (RBC, Wells Fargo, Chardan) have issued more favorable notes recently, supporting a rebound narrative for the stock. Mizuho Upgrade
• Positive Sentiment: H.C. Wainwright reaffirmed a Buy rating and kept a $70 price target, citing regulatory shifts and AMT‑130 outlook as catalysts that could drive long-term upside. H.C. Wainwright Note
• Neutral Sentiment: Shares previously spiked (~26% reported) on an FDA leadership shakeup that some investors hoped would favor uniQure’s Huntington’s therapy pathway — a short-term momentum event that may have already priced in expectations. MSN Coverage
• Negative Sentiment: Regulatory risk intensified after reports that the FDA publicly rebuked uniQure, alleging the company pushed “distorted” or “manipulated” data around the failed AMT‑130 program — a serious development that raises oversight, approval, and credibility concerns. FDA Allegation Report
• Negative Sentiment: Multiple plaintiff firms have filed or are soliciting investors for securities‑fraud class actions tied to uniQure’s FDA delays and share decline, creating legal overhang, potential liabilities, and continued headline risk that can pressure the stock. Kessler Topaz Filing
• Negative Sentiment: Short interest jumped significantly in February (over 17% increase), now representing ~21% of float — a condition that can amplify downside on negative news and reflects elevated bearish positioning.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.